

Cheat sheet: pediatric FDA-approved therapies by age (AD)

Use as a starting point; choice depends on severity, site, and access. (US FDA labels)

Age	Topical anti-inflammatory options	Systemic options
≥3 mo	Crisaborole (PDE4) + topical steroids / moisturizers	—
≥6 mo	All above	Dupilumab
2–5 y	Tacrolimus 0.03%; Pimecrolimus Roflumilast 0.05% Ruxolitinib 1.5% cream Tapinarof	Dupilumab
≥6 y	Roflumilast 0.15% (in addition to above)	Dupilumab
≥12 y	All above	Dupilumab Tralokinumab Lebrikizumab (≥40 kg) Nemolizumab Upadacitinib Abrocitinib

Tapinarof cream, for topical use. US Food and Drug Administration (FDA) approved product information. Revised December 2024. US Food and Drug Administration. https://www.accessdata.fda.gov/drugatfda_docs/label/2024/215272s002bl.pdf (Accessed on January 02, 2025).
Frohna JO. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. *J Pediatr.* 2005;147(1):126. doi:10.1016/j.jpeds.2005.04.051
Zane LT, Kirck L, Call R, et al. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. *Pediatr Dermatol.* 2016;33(4):380-387. doi:10.1111/pde.12872
Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. *JAMA Dermatol.* 2024;160(11):1161-1170. doi:10.1001/jamadermatol.2024.3121
Tapinarof cream, for topical use. US Food and Drug Administration (FDA) approved product information. Revised December 2024. US Food and Drug Administration. https://www.accessdata.fda.gov/drugatfda_docs/label/2024/215272s002bl.pdf (Accessed on January 02, 2025).